Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Endothelial Protein C Receptor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    18 result(s) found for: Endothelial Protein C Receptor. Displaying page 1 of 1.
    EudraCT Number: 2020-002940-22 Sponsor Protocol Number: STARDUST Start Date*: 2021-01-13
    Sponsor Name:A.O.U. Università degli Studi della Campania "Luigi Vanvitelli"
    Full Title: EFFECTS OF THE GLP-1 RECEPTOR AGONIST LIRAGLUTIDE ON LOWER LIMB PERFUSION IN PEOPLE WITH TYPE 2 DIABETES AND PERIPHERAL ARTERY DISEASE: A RANDOMIZED CONTROLLED TRIAL
    Medical condition: Peripheral Artery Disease and type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10053246 Type II diabetes peripheral angiopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004580-39 Sponsor Protocol Number: TOSCA_GHDDP Start Date*: 2018-07-18
    Sponsor Name:AOU FEDERICO II
    Full Title: Treatment of Growth Hormone Deficiency associated with Chronic Heart Failure: A Randomized, Double-Blind, Placebo-Controlled Study
    Medical condition: Growth Hormone Deficiency associated with Chronic Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003175-19 Sponsor Protocol Number: U1111-1206-7541 Start Date*: 2019-11-28
    Sponsor Name:Steno Diabetes Center Copenhagen
    Full Title: Renal effects of treatment with Empagliflozin alone or in combination with Semaglutide in patients with type 2 diabetes and albuminuria - A double blinded, randomised, placebo controlled, parallel...
    Medical condition: Type 2 diabetes with renal complications
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001172-15 Sponsor Protocol Number: APN01-01-COVID19 Start Date*: 2020-04-08
    Sponsor Name:APEIRON Biologics AG
    Full Title: Recombinant human angiotensin-converting enzyme 2 (rhACE2) as a treat-ment for patients with COVID-19
    Medical condition: Severe COVID-19 POSITIVE hospitalized male or female, between 18 and ≤ 80 years of age
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) AT (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2018-002686-19 Sponsor Protocol Number: 2018-HJEPharma-001 Start Date*: 2018-11-07
    Sponsor Name:Department of Cardiology, Copenhagen University Hospital Rigshospitalet
    Full Title: Interleukin-6 Receptor Antibodies for Modulating the Systemic Inflammatory Response after Out-of-Hospital Cardiac Arrest
    Medical condition: We investigate the efficacy of commercially available interleukin-6 receptor antibody 'RoActemra' for reducing the systemic inflammatory response in patients having been resuscitated after out-of-h...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007515 Cardiac arrest PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-000065-20 Sponsor Protocol Number: LPS15919 Start Date*: 2020-02-05
    Sponsor Name:Sanofi Aventis Groupe (SAG)
    Full Title: A randomized, open-label, active comparator, 2-arm, prospective study to assess the glycosphingolipid clearance and clinical effects of switching to agalsidase beta (Fabrazyme®) versus continuing o...
    Medical condition: Fabry disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10016016 Fabry's disease PT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: NO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-000064-21 Sponsor Protocol Number: LPS15918 Start Date*: Information not available in EudraCT
    Sponsor Name:Sanofi Aventis Groupe (SAG)
    Full Title: A randomized, open-label, active comparator, 2-arm, prospective study to assess the glycosphingolipid clearance and clinical benefits of agalsidase beta (Fabrazyme®) in male patients with classic F...
    Medical condition: Fabry's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10016016 Fabry's disease PT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: NO (Prematurely Ended) CZ (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020426-18 Sponsor Protocol Number: IMCLCP12-0922 Start Date*: 2010-10-27
    Sponsor Name:ImClone LLC
    Full Title: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) Drug Product in Patients With Metastatic Gastric Adenocarcinom...
    Medical condition: Metastatic gastric or gastroesophageal adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063916 Metastatic gastric cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) HU (Completed) RO (Completed) FR (Completed) GB (Completed) AT (Completed) LT (Completed) PT (Completed) EE (Completed) IT (Completed) BE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2019-004418-32 Sponsor Protocol Number: U31402-A-U202 Start Date*: 2020-10-30
    Sponsor Name:DAIICHI SANKYO, INC
    Full Title: A MULTI-CENTER, OPEN-LABEL, PHASE 2 STUDY TO EVALUATE SAFETY AND EFFICACY OF U3-1402 IN SUBJECTS WITH ADVANCED OR METASTATIC COLORECTAL CANCER (CRC)
    Medical condition: Advanced or metastatic colorectal cancer (CRC) which is resistant, refractory, or intolerant to at least 2 prior lines of therapy, that must include all of the following agents: fluoropyrimidine, i...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) PL (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005666-36 Sponsor Protocol Number: IBCSG 22-00 Start Date*: 2009-12-07
    Sponsor Name:International Breast Cancer Study Group
    Full Title: Low-dose Cytotoxics as “Anti-angiogenesis Treatment” following Adjuvant Induction Chemotherapy for Patients with ER-negative and PgR-negative Breast Cancer Maintenance Chemotherapy in Hormone Non-...
    Medical condition: Histologically proven ER-negative and PgRnegative breast cancer with either a total mastectomy with axillary clearance or a lesser procedure with axillary lymph node dissection or sentinel node pro...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006190 Breast cancer invasive NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001724-35 Sponsor Protocol Number: AMASCIS-02 Start Date*: 2020-06-16
    Sponsor Name:Fundación para la Investigación Biomédica del Hospital Universitario de La Paz (FIBHULP)
    Full Title: AMASCIS-02. ALOGENIC ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS IN ISCHEMIC STROKE. A PHASE IIB MULTICENTER DOUBLE BLIND PLACEBO CONTROLLED CLINICAL TRIAL.
    Medical condition: Moderate-severe ischemic stroke
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004852 10055221 Ischemic stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004152-19 Sponsor Protocol Number: ELASTIC2011 Start Date*: 2012-04-18
    Sponsor Name:Ludwig Boltzmann institute for COPD and Respiratory Epidemiology
    Full Title: Effects of ROFLUMILAST on markers of subclinical atherosclerosis In stable COPD; the ELASTIC-trial
    Medical condition: chronic obstructive pulmonary disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-003243-21 Sponsor Protocol Number: XL092-303 Start Date*: 2022-10-06
    Sponsor Name:Exelixis, Inc.
    Full Title: A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer
    Medical condition: Metastatic colorectal cancer (CRC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) PT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002563-25 Sponsor Protocol Number: VEGF-RTX-2013 Start Date*: 2014-01-13
    Sponsor Name:VU University Medical Centre
    Full Title: Pilot study to determine the effect of fractionated radiotherapy on expression of pro-angiogenic factors in oeshophagus carcinoma
    Medical condition: Angiogenesis in esophageal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10015362 Esophageal cancer LLT
    20.0 100000004864 10030151 Oesophageal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-000528-39 Sponsor Protocol Number: TAK-676-1002 Start Date*: 2023-03-20
    Sponsor Name:Takeda Development Center Americas, Inc. (TDC Americas)
    Full Title: An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Ad...
    Medical condition: Solid Neoplasms
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-001726-13 Sponsor Protocol Number: A4061038 Start Date*: 2008-11-28
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York City, NY 10017
    Full Title: PHASE 2 TRIAL OF AG-013736 AS FIRST-LINE TREATMENT FOR PATIENTS WITH SQUAMOUS NON-SMALL CELL LUNG CANCER RECEIVING TREATMENT WITH CISPLATIN AND GEMCITABINE
    Medical condition: Advanced non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059515 Non-small cell lung cancer metastatic PT
    9.1 10029515 Non-small cell lung cancer recurrent LLT
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-006682-33 Sponsor Protocol Number: A4061030 Start Date*: 2008-03-20
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017, USA
    Full Title: Randomzied Phase 2 Trial of AG-013736 or Bevacizumab in Combination with Paclitaxel and Carboplatin as First Line Treatment For Patients with Advanced Non-small Cell Lung Cancer
    Medical condition: First line treatment of patients with unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059515 Non-small cell lung cancer metastatic PT
    9.1 10029515 Non-small cell lung cancer recurrent LLT
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) CZ (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-004842-92 Sponsor Protocol Number: SECOMBIT Start Date*: 2016-06-30
    Sponsor Name:FONDAZIONE MELANOMA ONLUS
    Full Title: A three arms prospective, randomized phase II study to evaluate the best sequential approach with combo immunotherapy (ipilimumab/nivolumab) and combo target therapy (LGX818/MEK162) in patients wit...
    Medical condition: Metastatic melanoma and BRAF mutation
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing) ES (Ongoing) DE (Completed) GR (Completed) AT (Ongoing) GB (GB - no longer in EU/EEA) SE (Ongoing) PL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 02:20:17 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA